Milademetan, an oral MDM2 inhibitor, in well-differentiated/ dedifferentiated liposarcoma: results from a phase 1 study in patients with solid tumors or lymphomas
暂无分享,去创建一个
P. LoRusso | G. Schwartz | M. Gounder | D. Hong | T. Bauer | P. Kumar | Y. Hong | K. Kato | B. Tao | P. Kumar | P. Patel | Y. Hong